RAC1 Regulates Shh-Medulloblastoma Growth via GLI-Mediated Transcription
Nitish JangdeiD, M J LeeiD, Luz Clarita RuiziD, Isabelle EganiD, Anna M. JermakowicziD, Rishika ChowdaryiD, Jonathan ChuiD, Daniel T. WynniD, Erik T. Goka, M. E. Lippman, David J. RobbinsiD, Nagi G. AyadiD
Abstract
Medulloblastoma (MB) is the most common malignant primary pediatric brain tumor. Current therapies are ineffective for targeting proliferation, leptomeningeal migration, and metastasis of MB cancer cells to visceral organs and therefore, novel treatments are needed. The small GTPase, RAC1, has emerged as an important regulator of actin cytoskeletal dynamics, proliferation, and migration in several cancers. However, it has not been characterized in MB and no clinical drug candidates have been described for RAC1 in MB. Here we demonstrate that RAC1 levels are higher in MB tissue relative to normal cerebellum. Further, RAC1 depletion significantly reduces proliferation and migration of Shh-MB cells in vitro. Mechanistically, RAC1 controls the mRNA and protein levels of the main transcription factors in the Shh pathway, GLI1 and GLI2. RAC1 binds to the GLI1 promoter highlighting a novel role in transcriptional regulation in Shh-dependent cancers. We demonstrate that the RAC1 inhibitor, GYS32661, is brain penetrant, and reduces MB growth and increases mouse survival in an orthotopic model of Shh-MB. Importantly, GYS32661 is a non-toxic clinical candidate, suggesting that it may be a novel potential drug for the treatment of either the pediatric or adult forms of MB. Collectively, our studies identify RAC1 as a druggable target in Shh-dependent MB. Graphical abstractRAC1 controls Shh-MB progression by binding to the GLI1 promoter. Graphical abstract demonstrating RAC1 localizes to the nucleus and binds to the GLI1 promoter and plays an important role in its transcription. RAC1 genetic or GYS32661 mediated inhibition leads to RAC1 dissociation from the GLI1 promoter and transcriptional repression of Shh-MB biomarkers GLI2, DNMT1 and UHRF1. This eventually causes inhibition of Shh-MB tumor cell proliferation and migration, which leads to a decrease in Shh-MB development. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=118 SRC="FIGDIR/small/655563v2_ufig1.gif" ALT="Figure 1"> View larger version (37K): org.highwire.dtl.DTLVardef@e4def9org.highwire.dtl.DTLVardef@1eab826org.highwire.dtl.DTLVardef@dfe68borg.highwire.dtl.DTLVardef@198efb9_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 13th percentile
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Ras-Responsive Element Binding Protein 1 regulates survival of Group 3 medulloblastoma
Meher Beigi Masihi, Kendall R. Chambers, … Robert J. Wechsler‐Reya·bioRxiv·Jul 16, 2025
- Multifaceted functions of Rab23 on primary cilium and Hedgehog signaling-mediated granule cell proliferation
Catherine Hong Huan Hor, J. C. W. Lo, … Eyleen L. K. Goh·Journal of NeurosciencePeer-reviewed·Jul 1, 2021
- Modulation of Viability, Proliferation, and Stemness by Rosmarinic Acid in Medulloblastoma Cells: Involvement of HDACs and EGFR
A. L. Herlinger, G. L. Michaelsen, … R. Roesler·bioRxiv·Aug 10, 2023
- Preclinical assessment of MAGMAS inhibitor as a potential therapy for pediatric medulloblastoma
Zahra Motahari, Javier J. Lepe, … Daniela Annenelie Bota·PLoS ONEPeer-reviewed·Oct 22, 2024
- Activation of the mevalonate pathway in response to anti-cancer treatments drives glioblastoma recurrences through activation of Rac-1
Ling He, Angeliki Diotima Ioannidis, … Frank Pajonk·Cancer Research CommunicationsPeer-reviewed·Jun 5, 2024
- HDAC and MAPK/ERK inhibitors cooperate to reduce viability and stemness phenotype in medulloblastoma
M. d. C. Jaeger, E. C. Ghisleni, … R. Roesler·bioRxiv·Jan 30, 2020